Loading stock data…
$1.60-0.01 (-0.62%)
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
Lexicon Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.60 with a market capitalization of $779M. Wall Street consensus targets $4.55 (6 analysts), implying a +184.2% move over the next 12 months. The stock is currently 40% below its 52-week high of $2.68, remaining 14.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $692,000↓ | $21.10M↑ | $5.49M↓ | $14.18M↓ | $28.87M |
| Gross Profit | $653,000↓ | $20.99M↑ | $5.29M↓ | $14.17M↓ | $28.83M |
| Operating Income | -$26.54M↓ | -$996,000↑ | -$14.78M↓ | -$12.19M↓ | $3.74M |
| Net Income | -$31.77M↓ | -$1.04M↑ | -$15.53M↓ | -$12.77M↓ | $3.25M |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small mole...